TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06418711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine Inhalation Suspension
Description: Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
Study: NCT06435169

Intervention type: DIAGNOSTIC_TEST
Intervention: Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.
Description: The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.
Description: The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
Study: NCT06085989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant directed singing
Description: In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
Study: NCT06455683

Intervention type: PROCEDURE
Intervention: Glaucoma Surgery
Description: One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment
Study: NCT04603508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BERLIM 25/10 association
Description: Berlim 25/10 association coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMPAGLIFLOZIN
Description: Empagliflozin 25 mg coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROSUVASTATIN CALCIUM
Description: Rosuvastatin 10 mg coated tablet.
Study: NCT06423339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Genicular nerve block
Description: Ultrasound guided genicular nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
Description: Ultrasound guided Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: Ultrasound guided sub-sartorial Adductor canal block
Study: NCT04603508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BERLIM 25/10 ASSOCIATION PLACEBO
Description: Berlim 25/10 association placebo coated tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPAGLIFLOZIN PLACEBO
Description: Empagliflozin placebo coated tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROSUVASTATIN CALCIUM PLACEBO
Description: Rosuvastatin placebo coated tablet.
Study: NCT04810390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Ophthalmic solution 0.6%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic solution
Study: NCT05937269

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence lymphatic imaging
Description: All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Near-infrared fluorescence lymphatic imaging
Description: All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
Study: NCT06423339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Pupivacaine 0.5% in 20 ml vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Pupivacaine 0.5% in 20 ml vial
Study: NCT05196815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheters
Description: During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft study wire
Description: Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-ray
Description: Participants will have chests x-ray when the soft study wire is inserted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
Study: NCT05621187

Intervention type: DEVICE
Group type: OTHER
Intervention: Pamira ICD lead family
Description: Implantation, measurements and follow-up schedule
Study: NCT05992259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
Study: NCT06474091

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT05937269

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared fluorescence lymphatic imaging
Description: All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: advanced pneumatic compression therapy
Description: The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
Study: NCT05783778

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Free testosterone levels and toxoplasma igG
Description: Free testosterone levels and toxoplasma igG in serum by ELISA

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Free testosterone levels and toxoplasma igG
Description: Free testosterone levels and toxoplasma igG in serum by ELISA
Study: NCT04990388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic
Study: NCT06297616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3841136-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3841136-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirzepatide-Placebo
Description: Administered SC
Study: NCT06478550

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.
Study: NCT06000098

Intervention type: OTHER
Intervention: Restrictive fluid therapy
Description: 0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
Study: NCT06347536

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Supported rescue pack
Description: 1) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
Study: NCT05131399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase A1
Description: Plastic standard ankle foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase B1
Description: carbon medical device ankle foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase A2
Description: Plastic standard ankle foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase B2
Description: carbon medical device ankle foot orthosis
Study: NCT06191744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV Infusion
Study: NCT05728463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
Study: NCT04949126

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: questionnaires of precarity, dental anxiety, self medication, pain

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: questionnaires of precarity, dental anxiety, self medication, pain
Study: NCT05947812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine Oral Tablet
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
Study: NCT04915989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-19N
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
Study: NCT05143307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBT-101
Description: Long term follow up of participants who received EBT-101
Study: NCT06655493

Intervention type: OTHER
Intervention: No treatment given
Description: Participants will continue their normal care and will not get any treatment as part of this study.

Intervention type: OTHER
Intervention: No treatment given
Description: Participants will continue their normal care and will not get any treatment as part of this study.
Study: NCT06587282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloom Micro Occluder System
Description: Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
Study: NCT06184815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational programme 12
Description: Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education and treatment
Description: Outpatient management and education in the office and consultation referral to nutrition and psychology
Study: NCT05152901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiPen ®.
Description: A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
Study: NCT04990388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX053
Description: mRNA-based biologic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: consists of the same components as the formulation buffer for UX053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: consists of the same components as the formulation buffer for UX053
Study: NCT06390540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
Study: NCT06605859

Intervention type: DEVICE
Intervention: GlucoTab
Description: Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab.

Intervention type: OTHER
Intervention: Diabetes Treatment
Description: Diabetes Standard Care
Study: NCT06607146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Success
Description: Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
Study: NCT06607094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
Study: NCT06608797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning and memory training
Description: The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).